Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 07/23/15 -- announced today that it has initiated coverage on (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc. (''IMNP''), headquartered in New York, is a clinical stage biopharmaceutical company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. IMNP''s lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with future studies planned for Crohn''s disease, severe asthma, NASH and atopic dermatitis." Mr. Silver continues, "On July 14, 2015 Celgene Corporation (CELG) and Receptos, Inc. (RCPT) announced the signing of a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2B, net of cash acquired. The transaction adds Ozanimod, which has demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), among others. Having Receptos as a comparison may be beneficial to IMNP as we may now be able to understand from a monetary perspective the value a compound intended to treat UC amongst others is worth."
To download a FREE copy of the (NASDAQ: IMNP) research report, please visit and click the "Download Research" icon to gain access to the report. stocks, such as those included in the iShares Nasdaq Biotechnology (NASDAQ: IBB), may continue to outperform the broader market in the back half of 2015.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm''s professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista''s mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Please follow us on & at Vista-Partners to receive updates, thoughts and ideas about our coverage universe of companies and more.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click .
Contact:
Vista Partners
877.215.4813
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.07.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 1374158
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
"
steht unter der journalistisch-redaktionellen Verantwortung von
Vista Partners LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
